Abstract
The many questions on the use of biomarkers for neurodegenerative diseases in clinical practice
Highlights
There are two basic questions always raised when biomarkers are proposed to be used for diagnosing neurodegenerative diseases (ND) in clinical practice (Wilner, 2010)
The second question is, does the additional diagnostic accuracy provided by biomarkers really matter? In clinical practice, a test that confirmed or ruled out a ND would remove uncertainty
If there is not a diseasemodifying therapy yet, what is the importance of an early diagnosis in routine clinical practice today? There are several reasons to make an early diagnosis even when we cannot modify the course of the disease
Summary
There are two basic questions always raised when biomarkers are proposed to be used for diagnosing neurodegenerative diseases (ND) in clinical practice (Wilner, 2010). The best argument for using biomarkers in clinical practice would be the possibility of treating patients with a disease-modifying therapy that prevents or delays the progression of the disease. No drug have proven prevention of any ND yet.The current therapies only provide symptomatic improvement at best so there is an urgent need to discover neuroprotective treatments.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
